# PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials

A. Italiano, Carine Bellera, S. d'Angelo

► To cite this version:

A. Italiano, Carine Bellera, S. d'Angelo. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. Journal of Hematology and Oncology, 2020, 13 (1), pp.55. 10.1186/s13045-020-00891-5 . hal-03122472

HAL Id: hal-03122472

https://hal.science/hal-03122472

Submitted on 27 Jan 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>
## LETTER TO THE EDITOR

Open Access

# PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials

Antoine Italiano<fnref n="1" />,<fnref n="2" />*, Carine Bellera³,⁴ and Sandra D'Angelo⁵,⁶

<figure><img src="image_2.png" /></figure>

### Abstract

Immune checkpoint inhibitors, especially the programmed cell death receptor-1/ligand 1 (PD-1/L1) inhibitors, displayed promising efficacy in several solid tumor types and hematological malignancies. Data related to their activity in soft-tissue sarcomas (STS) are scarce.

We performed a pooled analysis of clinical trials investigating a PD1 or PD-L1 antagonist in patients with advanced STS. Three hundred eighty-four patients were included in the pooled analysis; of those, 153 (39.8%) received a PD1/PD-L1 antagonist as a single agent. In patients treated with anti-PD1/PDL1 as a single agent, the overall response rate (ORR) and non-progression rate (NPR) were 15.1% and 58.5% respectively. In patients treated with a combination regimen, the ORR and NPR were 13.4% and 55.8% respectively. Analysis by histological subtype revealed that patients with alveolar soft part sarcoma and undifferentiated pleomorphic sarcoma exhibited the highest response rates and leiomyosarcoma the lowest. PD-L1 expression rate was low and inconsistently associated with objective response. PD-1/PD-L1 antagonists have limited activity in unselected STS. Future studies should implement histology and immune-based stratification of STS in their design as well as sequential blood and tissue sampling to better understand the mechanisms of resistance and response given sarcomas inherent heterogeneity.

**Keywords:** Sarcoma, Immunotherapy, Pooled analysis

To the editor,

Several phase II studies investigating the activity of PD1/PD-L1 targeting in soft-tissue sarcoma (STS) patients have been recently reported. All of them were characterized by a limited sample size and high heterogeneity in terms of histological subtypes. Here, we report a pooled analysis of these studies in order to get insight on the global activity of PD1/PD-L1 in STS and according to histological subtype.

Trials investigating a PD1 or PD-L1 antagonist in patients with advanced STS were eligible for this pooled analysis if they were registered in a public trials' registry.

The efficacy results had to be published in English in a peer-reviewed journal or presented in Proffered paper sessions of an annual meeting of the American Association of Cancer Research, American Society of Clinical Oncology, Connective Tissue of Oncology Society, or European Society of Medical Oncology up to June 30, 2019.

Objective response (OR), stable disease (SD), progressive disease (PD), and non-evaluable (NE) patients were defined as per RECIST v1.1. Investigational treatment was described according to 2 (monotherapy vs. combination therapy) or 3 classes (monotherapy, combination of PD1/PD-L1 antagonist with another immunotherapy, or combination of PD1 or PD-L1 antagonist with another type of treatment). Main histological subtypes included undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), leiomyosarcoma (LMS), alveolar soft

<footnote>* Correspondence: a.italiano@bordeaux.unicancer.fr</footnote>

<footnote n="1">¹Early Phase Trials and Sarcoma Units, Institut Bergonié, 229 Cours de l'Argonne, Bordeaux, France</footnote>

<footnote n="2">²University of Bordeaux, Bordeaux, France
Full list of author information is available at the end of the article</footnote>
part sarcoma (ASPS), and other STS. Additional details are available in **Supplementary Methods**.

Nine multicenter clinical trials met eligibility criteria for this pooled analysis (supplementary Table 1). Overall, 384 patients were included; of those, 153 (39.8%) received a PD1 or PD-L1 antagonist as a single agent.

Overall, objective response rate (ORR) and non-progression rate (NPR) were 15.1% (95% CI [8.6%; 25.1%]) and 58.5% (95% CI [44.4%; 71.3%]) respectively (Table 1). In patients treated with anti-PD1 or anti-PDL1 as a single agent, the ORR and NPR were 18.7% (95% CI [2.1%; 71.6%]) and 63.6% (95% CI [25.3%; 90.0%]) respectively. In patients treated with a combination regimen, the ORR and NPR were 13.4% (95% CI [6.0%; 27.1%]) and 55.8% (95% CI [35.0%; 74.8%]) respectively. These results do not suggest an association between the ORR (or NPR) and the investigational strategy (anti-PD1 or anti-PDL1 used as a single agent or in combination with another immunomodulatory drug or another class of anti-cancer agent).

ORR and NPR were 15.7% (95% CI [7.5%; 30.0%]) and 50.5% (95% CI [39.0%; 61.9%]) for UPS, 7.3% (95% CI [1.2%; 33.7%]) and 54.5% (95% CI [24.5%; 81.6%]) for LPS, 6.9% (95% CI [2.0%; 21.3%]) and 54.1% (95% CI [29.3%; 77.0%]) for LMS, 48.8% (95% CI [26.0%; 72.0%]) and 80.5% (95% CI [54.1%; 93.5%]) for ASPS, and 10.3% (95% CI [5.0%; 20.2%]) and 52.1% (95% CI [35.5%; 68.3%]) for other sarcomas (supplementary table 2).

Three clinical trials reported data related to PD-L1 expression status. Overall PD-L1 expression (≥ 1%) in tumor cells was observed in 21 (13.6%) out of 154 patients with available data. Twenty of them were

evaluable for response: 6 had an objective response for an ORR of 30% in PDL1-positive tumors. Among the 133 patients with PD-L1-negative status, nine had an objective response.

The low level of PD-L1 expression we have observed here is in agreement with previously reported retrospective studies using validated anti-PD-L1 immunohistochemical assays [1]. Although the proportion of objective responses is higher in patients with PD-L1-positive tumors, responses were also observed in PD-L1 negative cases. This highlights the limitation of PD-L1 expression as a predictive biomarker.

Data related to the genetic and immunologic landscape of STS are scarce. Pollack et al. reported a study investigating the immune phenotype of the most common individual STS subtypes in a series of 87 cases [2]. The authors found that UPS had the highest levels of PD-L1 and of PD-1 expression as well as the highest level of T cell infiltration in comparison with other histological subtypes. These results suggested that UPS were more likely to respond to immune checkpoint inhibitors and our pooled analysis confirmed this assumption.

Previous studies have already shown that LMS are poorly infiltrated by T cells [1]. Pre-existing T cell antitumour immunity has been hypothesized as a prerequisite to the anti-PD-1/PD-L1 response. Altogether, these results may explain the extremely low response rate to PD1/PDL1 inhibition observed in LMS and the need to investigate innovative strategies to modify the microenvironment of these tumors

<table><caption>**Table 1** Pooled analysis of efficacy of PD1/PD-L1 antagonist in soft-tissue sarcomas</caption><thead><tr><th colspan="6">All population (n = 384)</th></tr><tr><th></th><th></th><th>ORR</th><th></th><th>NPR</th><th></th></tr></thead><tbody><tr><td></td><td></td><td>15.1</td><td></td><td>58.5</td><td></td></tr><tr><td></td><td></td><td>95% CI 8.6%; 25.1%</td><td></td><td>95% CI 44.4%; 71.3%</td><td></td></tr><tr><th colspan="6">Efficacy by histological subtype</th></tr><tr><th>Histological subtype</th><th>N patients</th><th>ORR</th><th></th><th>NPR</th><th></th></tr><tr><td></td><td></td><td>%</td><td>95% CI</td><td>%</td><td>95% CI</td></tr><tr><td>UPS</td><td>103</td><td>15.7</td><td>7.5-30.0</td><td>50.5</td><td>39.0-61.9</td></tr><tr><td>LMS</td><td>82</td><td>6.9</td><td>2.0-21.3</td><td>54.1</td><td>29.3-77.0</td></tr><tr><td>DDLPS</td><td>61</td><td>7.3</td><td>1.2-33.7</td><td>54.5</td><td>24.5-81.6</td></tr><tr><td>ASPS</td><td>41</td><td>48.8</td><td>26.0-72.0</td><td>80.5</td><td>54.1-93.5</td></tr><tr><td>Others</td><td>97</td><td>10.3</td><td>5.0-20.2</td><td>52.1</td><td>35.5-68.3</td></tr><tr><th colspan="6">Efficacy by the therapeutic strategy</th></tr><tr><td>PD1/PD-L1 single agent</td><td>153</td><td>18.7</td><td>2.1-71.6</td><td>63.6</td><td>25.3-90.0</td></tr><tr><td>Combination with other immunotherapy</td><td>114</td><td>11.4</td><td>3.5-31.4</td><td>57.9</td><td>18.2-89.4</td></tr><tr><td>Combination with non-immunological agent</td><td>117</td><td>14.0</td><td>0.5-84.2</td><td>53.8</td><td>7.9-94.0</td></tr></tbody></table>

ASPS alveolar soft part sarcoma, DDLPS liposarcoma, LMS leiomyosarcoma, ORR objective response rate, NPR non-progression rate, UPS undifferentiated pleomorphic sarcoma
which are characterized by a strong infiltration by M2 macrophages [3].

We noted an ORR about 8% in DDLPS suggesting the need for alternative strategies to galvanize an immune response. CKD4 inhibitors have demonstrated some efficacy in DDLPS which are characterized by a strong CDK4 amplification [4, 5]. Combination of PD1/PD-L1 antagonists with such agents, which have been shown to enhance immunogenicity of tumor cells, can represent a potential promising approach [6].

Our pooled analysis suggests also that PD1/PD-L1 targeting may have also a role in translocation-associated sarcomas. Indeed, the highest objective response rate has been observed in ASPS with nearly 50% of patients having an objective response. However, the mechanisms which are driving the immunogenicity of this ultra-rare sarcoma remain to be elucidated.

Overall, this pooled analysis underscores the need for future studies implementing a histology and immune-based stratification of STS patients in their design. Petitprez et al. have reported an immune-based classification of complex genomics STS; transcriptomic profile of a cohort of 608 STS was performed utilizing the microenvironment cell populations-counter (MCP-counter) method [7]. Tumors were assigned to one of five sarcoma immune classes (SICs), labeled A, B, C, D, and E, with SIC A, "immune desert," being characterized by the lowest expression of gene signatures related to immune cells and SIC E being characterized by the highest expression of genes specific of immune populations such as T cells, CD8+ T cells, NK cells, and cytotoxic lymphocytes. Interestingly, intra-tumoral tertiary lymphoid structures (TLS) were identified as a hallmark of the inflamed SIC E group [7]. There are accumulating evidence indicating that TLS play a crucial role in antitumor immune responses by favoring presentation of tumor antigens by dendritic cells and education of subsequent T and B cell responses, resulting in the production of T effector memory cells, memory B cells, and antibodies [8]. Their presence can be easily assessed by immunohistochemistry and has been associated with improved outcome in several tumor types [8]. Utilizing tumor specimens from SARC028, Petitprez et al. demonstrated that, when treated with pembrolizumab, patients with SIC E tumors, which are characterized by the presence of TLS, exhibit significantly higher ORR and progression-free survival than others [7]. Indeed, the objective response rate was 50% in SIC E patients versus 25% in SIC D and 22% in SIC, *p* = 0.026. In addition, CR were only found in SIC E and no responder was found in SIC A and B [7]. These data suggest that using TLS as a biomarker may represent a promising approach to tailor immunotherapy in sarcoma patients.

**Supplementary information**

**Supplementary information** accompanies this paper at https://doi.org/10.1186/s13045-020-00891-5.

**Additional file 1.** Supplementary methods and results

**Abbreviations**

NE: Non-evaluable; OR: Objective response; ORR: Overall response rate; PD: Progressive disease; PD1: Programmed cell death 1; PD-L1: Programmed death-ligand 1; SD: Stable disease; STS: Soft-tissue sarcoma

**Acknowledgements**

None

**Authors' contributions**

Al and SA drafted the manuscript. CB performed the statistical analysis. All authors provided comments on previous versions of the manuscript. All authors read and approved the final manuscript.

**Funding**

None

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

Al has received research grants from Astra Zeneca, BMS, and MSD.

**Author details**

Received: 31 January 2020 Accepted: 5 May 2020

Published online: 19 May 2020

**References**

1. D'Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. *Hum Pathol.* 2014;46:357–65.

2. Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. *Cancer. 2017;123(17):3291–304.

3. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, Beck AH, Weissman IL, van de Rijn M. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. *Proc Natl Acad Sci U S A.* 2012 Apr 24;109(17):6656–61.

4. Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, Ustoyev Y, Crago AM, Singer S, Schwartz GK. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. *J Clin Oncol.* 2013 Jun 1;31(16):2024–8.

5. Dickson MA, Koff A, D'Angelo SP, Gounder MM, Keohan ML, Kelly CM, Chi P, Antonescu CR, Landa J, Qin L-X, Crago AM, Singer S, William D. Tap phase 2

<footnote n="1">¹Early Phase Trials and Sarcoma Units, Institut Bergonié, 229 Cours de l'Argonne, Bordeaux, France. ²University of Bordeaux, Bordeaux, France.</footnote>

<footnote n="3">³University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, F-33000 Bordeaux, France. ⁴Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France. ⁵Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁶Weill Cornell Medical College, New York, NY, USA.</footnote>
study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. J Clin Oncol. 2019;37(15_suppl):11004.

6. Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471-5.

7. Petitprez F, de Reyniès A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556-60.

8. Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019 Jun; 19(6):307-25.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

* fast, convenient online submission

* thorough peer review by experienced researchers in your field

* rapid publication on acceptance

* support for research data, including large and complex data types

* gold Open Access which fosters wider collaboration and increased citations

* maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

<figure><img src="image_3.png" /></figure>